441045-17-6
441045-17-6 結(jié)構(gòu)式
基本信息
艾瑞布林/甲磺酸艾瑞布林/甲磺酸艾日布林/艾日布林
E7389 mesylate
B1939 mesylate
Eribulin Mesylate
Eribulin Mesilate
ER-086526 mesylate
EribulinMesylate USP/EP/BP
Eribulin mesylate Halaven
物理化學(xué)性質(zhì)
常見問題列表
甲磺酸艾日布林是一種抗腫瘤藥物，可用于治療轉(zhuǎn)移性乳腺癌患者。
Eribulin (1-100 nM; 72 h) inhibits cells proliferation, with IC
50
s of 22.8 and 21.5 nM for LM8 and Dunn cells, respectively.
Eribulin (10-50 nM; 12-72 h) increases early apoptosis significantly after 24 h treatment at the dose of 50 nM in LM8 cells.
Eribulin (10-50 nM; 12-72 h) induces G2/M arrest by 12 h treatment with at the dose of 50 nM, but not by long-term treatment (72 h) with 10 nM in LM8 cells.
Eribulin (1-50 nM; 12 h) does not induce senescence in LM8 cells.
Eribulin (1-10 nM; 16 h) induces morphological change and suppresses cell migration in a low concentration in LM8 cells.
Cell Proliferation Assay
| Cell Line: | LM8 cells and Dunn cells |
| Concentration: | 0, 1, 10, 100 nM |
| Incubation Time: | 72 hours |
| Result: | Inhibited cells proliferation in a dose-dependent manner. |
Apoptosis Analysis
| Cell Line: | LM8 cells |
| Concentration: | 0, 10, 50 nM |
| Incubation Time: | 12, 24, 48, 72 hour |
| Result: |
Induced early apoptosis after 12 h at the concentration of 50 nM.
Not detected apoptosis at the concentration of 10 nM. |
Cell Cycle Analysis
| Cell Line: | LM8 cells |
| Concentration: | 0, 10, 50 nM |
| Incubation Time: | 12, 24, 48, 72 hour |
| Result: |
Induced G2/M arrest by 12 h treatment with 50 nM.
No G2/M arrest was induced by10 nM treatment. |
Eribulin (1 mg/kg; i.v. once a week for 2 weeks) reduces primary tumor growth and lung metastasis of osteosarcoma in mice.
Eribulin (1 mg/kg; once i.v.) suppresses circulating tumor cells (CTC) appearance in the low-concentration phase.
| Animal Model: | C3H/HeN mice (4-week-old) are injected LM8 cells |
| Dosage: | 1 mg/kg |
| Administration: | I.v. once a week for 2 weeks |
| Result: |
Suppressed primary tumor growth and induced apoptosis in tumor cells.
Reduced lung metastasis.
|